Cargando…

CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer

INTRODUCTION: Although immunotherapy works well in parts of patients with bladder cancer (BLCA), its overall response rate of anti-PD-1 inhibitors remains unsatisfactory. Besides, growing evidence shows that tumor-infiltrating lymphocytes (TILs) immunotherapy has demonstrated excellent efficacy in v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Wenjie, Zhao, Zihan, Feng, Baofu, Yu, Wenhao, Li, Ji, Guo, Hongqian, Yang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006912/ https://www.ncbi.nlm.nih.gov/pubmed/33790578 http://dx.doi.org/10.2147/OTT.S297272

Ejemplares similares

Intratumoral CD4(+) T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
por: Oh, David Y., et al.
Publicado: (2020)

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
por: Duhen, Thomas, et al.
Publicado: (2018)

CD39(+)PD-1(+)CD8(+) T cells mediate metastatic dormancy in breast cancer
por: Tallón de Lara, Paulino, et al.
Publicado: (2021)

CD39 Expression Identifies Terminally Exhausted CD8(+) T Cells
por: Gupta, Prakash K., et al.
Publicado: (2015)

Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses
por: Shevchenko, Ivan, et al.
Publicado: (2020)

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity
por: Zou, Fan, et al.
Publicado: (2021)

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects
por: Li, Tianhang, et al.
Publicado: (2021)

Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression
por: Li, Kunyu, et al.
Publicado: (2016)

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
por: Kashyap, Abhishek S., et al.
Publicado: (2019)

On the mechanism of anti-CD39 immune checkpoint therapy
por: Allard, David, et al.
Publicado: (2020)

CD39(+) conventional CD4(+) T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade
por: Bossio, Sabrina N., et al.
Publicado: (2023)

Cytotoxicity Is Mandatory for CD8(+) T Cell–mediated Contact Hypersensitivity
por: Kehren, Jeanne, et al.
Publicado: (1999)

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer
por: Workel, Hagma H., et al.
Publicado: (2020)

HMGN2, a new anti-tumor effector molecule of CD8(+) T cells
por: Su, Lin, et al.
Publicado: (2014)

MDSC subtypes and CD39 expression on CD8(+) T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
por: Koh, Jiae, et al.
Publicado: (2020)

Association between circulating CD39+CD8+ T cells pre-chemoradiotherapy and prognosis in patients with nasopharyngeal carcinoma
por: Dong, Dan-Ning, et al.
Publicado: (2021)

Correction: On the mechanism of anti-CD39 immune checkpoint therapy
Publicado: (2020)

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors
por: Aliagas, Elisabet, et al.
Publicado: (2014)

YAP Attenuates CD8 T Cell-Mediated Anti-tumor Response
por: Lebid, Andriana, et al.
Publicado: (2020)

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73(-) Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
por: Ahmadi, Parimah, et al.
Publicado: (2020)

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
por: van den Bulk, Jitske, et al.
Publicado: (2023)

CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity
por: Do, Manh-Hung, et al.
Publicado: (2022)

Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment
por: Liu, Lilong, et al.
Publicado: (2022)

CD39 as a marker of pathogenic CD8+ T cells in cancer and other chronic inflammatory diseases
por: Canale, Fernando Pablo, et al.
Publicado: (2018)

Evaluating adipose‐derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer
por: Liu, Tianyao, et al.
Publicado: (2022)

CD8+CD103+ iTregs Inhibit Chronic Graft-versus-Host Disease with Lupus Nephritis by the Increased Expression of CD39
por: Zhang, Xiao, et al.
Publicado: (2019)

Preoperative Risk Classification Using Neutrophil-to-Lymphocyte Ratio and Albumin for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
por: Zhao, Zihan, et al.
Publicado: (2020)

Cd8(+) but Not Cd8(−) Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
por: den Haan, Joke M.M., et al.
Publicado: (2000)

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
por: Brauneck, Franziska, et al.
Publicado: (2021)

Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis
por: Schirmer, Michael, et al.
Publicado: (2002)

Nucleotide Analog ARL67156 as a Lead Structure for the Development of CD39 and Dual CD39/CD73 Ectonucleotidase Inhibitors
por: Schäkel, Laura, et al.
Publicado: (2020)

Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer
por: Lubbers, Joyce M., et al.
Publicado: (2022)

CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
por: Niborski, Leticia Laura, et al.
Publicado: (2022)

CD39 Regulation and Functions in T Cells
por: Timperi, Eleonora, et al.
Publicado: (2021)

Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models
por: Zhang, Haohai, et al.
Publicado: (2022)

A cell-engineered system to assess tumor cell sensitivity to CD8(+) T cell-mediated cytotoxicity
por: Nelson, Nadine, et al.
Publicado: (2019)

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
por: Deaglio, Silvia, et al.
Publicado: (2007)

CD4(+) T cells support polyfunctionality of cytotoxic CD8(+) T cells with memory potential in immunological control of tumor
por: Imai, Naoko, et al.
Publicado: (2020)

High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer
por: Ferreira, Janaina Mendes, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8n9e330kk0pec6f296jv99giqb